Verrica Pharmaceuticals Inc. 1NE.F Stock
Verrica Pharmaceuticals Inc. Price Chart
Verrica Pharmaceuticals Inc. 1NE.F Financial and Trading Overview
| Verrica Pharmaceuticals Inc. stock price | 8.23 EUR |
| Previous Close | 5.65 EUR |
| Open | 5.75 EUR |
| Bid | 5.75 EUR x 0 |
| Ask | 5.8 EUR x 0 |
| Day's Range | 5.75 - 5.75 EUR |
| 52 Week Range | 1.8 - 7.9 EUR |
| Volume | 100 EUR |
| Avg. Volume | 32 EUR |
| Market Cap | 250.3M EUR |
| Beta (5Y Monthly) | 1.996883 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.64 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.83 EUR |
1NE.F Valuation Measures
| Enterprise Value | 182.15M EUR |
| Trailing P/E | N/A |
| Forward P/E | -3.5714285 |
| PEG Ratio (5 yr expected) | 0.1 |
| Price/Sales (ttm) | 28.976126 |
| Price/Book (mrq) | 3.7120721 |
| Enterprise Value/Revenue | 21.087 |
| Enterprise Value/EBITDA | -8.891 |
Trading Information
Verrica Pharmaceuticals Inc. Stock Price History
| Beta (5Y Monthly) | 1.996883 |
| 52-Week Change | 191.23% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.9 EUR |
| 52 Week Low | 1.8 EUR |
| 50-Day Moving Average | 5.63 EUR |
| 200-Day Moving Average | 4.34 EUR |
1NE.F Share Statistics
| Avg. Volume (3 month) | 32 EUR |
| Avg. Daily Volume (10-Days) | 70 EUR |
| Shares Outstanding | 41.85M |
| Float | 17.69M |
| Short Ratio | N/A |
| % Held by Insiders | 39.93% |
| % Held by Institutions | 23.73% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -261.70% |
| Operating Margin (ttm) | -242.82% |
| Gross Margin | -35.51% |
| EBITDA Margin | -237.18% |
Management Effectiveness
| Return on Assets (ttm) | -18.69% |
| Return on Equity (ttm) | -50.088% |
Income Statement
| Revenue (ttm) | 8.64M EUR |
| Revenue Per Share (ttm) | 0.23 EUR |
| Quarterly Revenue Growth (yoy) | -91.40% |
| Gross Profit (ttm) | 8.31M EUR |
| EBITDA | -20488000 EUR |
| Net Income Avi to Common (ttm) | -22606000 EUR |
| Diluted EPS (ttm) | -0.53 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 59.95M EUR |
| Total Cash Per Share (mrq) | 1.43 EUR |
| Total Debt (mrq) | 1.45M EUR |
| Total Debt/Equity (mrq) | 2.24 EUR |
| Current Ratio (mrq) | 23.873 |
| Book Value Per Share (mrq) | 1.549 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14900000 EUR |
| Levered Free Cash Flow (ttm) | 31.95M EUR |
Profile of Verrica Pharmaceuticals Inc.
| Country | Germany |
| State | PA |
| City | West Chester |
| Address | 44 West Gay Street |
| ZIP | 19380 |
| Phone | 484 453 3300 |
| Website | https://www.verrica.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 22 |
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Q&A For Verrica Pharmaceuticals Inc. Stock
What is a current 1NE.F stock price?
Verrica Pharmaceuticals Inc. 1NE.F stock price today per share is 8.23 EUR.
How to purchase Verrica Pharmaceuticals Inc. stock?
You can buy 1NE.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Verrica Pharmaceuticals Inc.?
The stock symbol or ticker of Verrica Pharmaceuticals Inc. is 1NE.F.
Which industry does the Verrica Pharmaceuticals Inc. company belong to?
The Verrica Pharmaceuticals Inc. industry is Biotechnology.
How many shares does Verrica Pharmaceuticals Inc. have in circulation?
The max supply of Verrica Pharmaceuticals Inc. shares is 42.42M.
What is Verrica Pharmaceuticals Inc. Price to Earnings Ratio (PE Ratio)?
Verrica Pharmaceuticals Inc. PE Ratio is now.
What was Verrica Pharmaceuticals Inc. earnings per share over the trailing 12 months (TTM)?
Verrica Pharmaceuticals Inc. EPS is -1.64 EUR over the trailing 12 months.
Which sector does the Verrica Pharmaceuticals Inc. company belong to?
The Verrica Pharmaceuticals Inc. sector is Healthcare.